Patents by Inventor Yumin TENG

Yumin TENG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic molecules that bind to LAG3 and PD1
    Patent number: 11951172
    Abstract: The invention relates to LAG-3 binding agents, in particular variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: April 9, 2024
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, Angelica Sette, Isabelle Osuch, Yumin Teng, James Legg, David Escors Murugarren
  • Single domain antibodies to programmed cell death (PD-1)
    Patent number: 11814429
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: November 14, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 (PD-1)
    Publication number: 20230357405
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: February 10, 2023
    Publication date: November 9, 2023
    Inventors: Phil HAYES, James LEGG, Martyna LEWANDOWSKA, Colette Johnston, Brian McGUINNESS, Mike ROMANOS, Christine ROSSANT, Yumin TENG
  • IL-17A binding proteins
    Patent number: 11667705
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 6, 2023
    Assignee: Crescendo Biologics Limited
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • TRANSGENIC MICE
    Publication number: 20230133028
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the reproduction of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Application
    Filed: October 19, 2022
    Publication date: May 4, 2023
    Applicant: Crescendo Biologics Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • Single domain antibodies to programmed cell death protein 1 (PD-1)
    Patent number: 11591398
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: February 28, 2023
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • Transgenic mice
    Patent number: 11547099
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: January 10, 2023
    Assignee: Crescendo Biologies Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • Single Domain Antibodies to Programmed Cell Death (PD-1)
    Publication number: 20220306744
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: March 29, 2022
    Publication date: September 29, 2022
    Inventors: Carolyn EDWARDS, James LEGG, Martyna LEWANDOWSKA, Colette JOHNSTON, Christine ROSSANT, Yumin TENG
  • Single-domain antibodies to programmed cell death 1 protein (PD-1), encoding nucleic acids and methods of using same
    Patent number: 11312771
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 26, 2022
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • THERAPEUTIC MOLECULES THAT BIND TO LAG3 AND PD1
    Publication number: 20210015937
    Abstract: The invention relates to LAG-3 binding agents, in particular particularly variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: February 18, 2019
    Publication date: January 21, 2021
    Inventors: Carolyn EDWARDS, Angelica SETTE, Isabelle OSUCH, Yumin TENG, James LEGG, David ESCORS MURUGARREN
  • SINGLE DOMAIN ANTIBODIES THAT BIND TO CD137
    Publication number: 20200362047
    Abstract: The disclosure relates to CD137 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: November 13, 2018
    Publication date: November 19, 2020
    Inventors: Verena BRUCKLACHER-WALDERT, Carolyn EDWARDS, James LEGG, Jayesh MAJITHIYA, Brian MCGUINNESS, Christine ROSSANT, Yumin TENG
  • IL-17A BINDING PROTEINS
    Publication number: 20200347127
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Application
    Filed: April 8, 2020
    Publication date: November 5, 2020
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH (PD-1)
    Publication number: 20200239573
    Abstract: The invention relates to PD-1 binding agents that block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 30, 2020
    Inventors: Phil Hayes, James Legg, Martyna Lewandowska, Colette Johnston, Brian McGuinness, Mike Romanos, Christine Rossant, Yumin Teng
  • SINGLE DOMAIN ANTIBODIES TO PROGRAMMED CELL DEATH (PD-1)
    Publication number: 20200239570
    Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: July 30, 2020
    Inventors: Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
  • IL-17A binding proteins
    Patent number: 10654924
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: May 19, 2020
    Assignee: CRESCENDO BIOLOGICS LIMITED
    Inventors: Bryan Edwards, Ulla Lashmar, Brian McGuinness, Mike Romanos, Thomas Sandal, Yumin Teng
  • Single Domain Antibodies to Programmed Cell Death (PD-1)
    Publication number: 20190322749
    Abstract: The invention relates to multifunctional PD-1 binding agents and the use of such binding agents in the treatment, prevention and detection of disease.
    Type: Application
    Filed: January 8, 2018
    Publication date: October 24, 2019
    Inventors: Carolyn Edwards, James Legg, Martyna Lewandowska, Colette Johnston, Christine Rossant, Yumin Teng
  • Methods for producing optimised therapeutic molecules
    Patent number: 10400030
    Abstract: The invention relates to a method of designing an immunoglobulin library for optimization of a biological property of a first lead immunoglobulin and libraries of optimized immunoglobulins produced by such methods.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: September 3, 2019
    Assignee: Crescendo Biologics Limited
    Inventors: Bryan Edwards, Yumin Teng
  • TRANSGENIC MICE
    Publication number: 20180362666
    Abstract: The invention relates to nucleic acid constructs for expression in mice for the production of heavy chain only antibodies and VH domains, transgenic mice, related methods and uses.
    Type: Application
    Filed: October 22, 2014
    Publication date: December 20, 2018
    Applicant: Crescendo Biologics Limited
    Inventors: Yumin Teng, Joyce Young, Brian McGuinness, Mike Romanos, Marianne Brueggemann
  • IL-17A BINDING PROTEINS
    Publication number: 20180118820
    Abstract: Binding molecules to IL-17A. The binding molecules are useful in the treatment of disorders, for example psoriasis.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 3, 2018
    Inventors: Bryan EDWARDS, Ulla LASHMAR, Brian MCGUINNESS, Mike ROMANOS, Thomas SANDAL, Yumin TENG
  • METHODS FOR PRODUCING OPTIMISED THERAPEUTIC MOLECULES
    Publication number: 20180002403
    Abstract: The invention relates to a method of designing an immunoglobulin library for optimisation of a biological property of a first lead immunoglobulin and libraries of optimised immunoglobulins produced by such methods.
    Type: Application
    Filed: January 12, 2016
    Publication date: January 4, 2018
    Applicant: Crescendo Biologics Limited
    Inventors: Bryan EDWARDS, Yumin TENG